Nasdaq: SLN+30.88% 24h move
Price before$11.95Aug 7, 2026, 4:00 PM ET
First trade after$17.43Aug 10, 2026, 7:58 AM ET
24h later$15.64Aug 11, 2026, 7:52 AM ET
Complete Announced during: Premarket · announced Mon 7:57a ET (premarket); before = Fri close; first trade Mon 7:58a ET; time = SEC 8-K acceptance
Silence Therapeutics (Nasdaq: SLN) reported topline results from a Phase 2 trial of divesiran on August 10, 2026. The company said the trial met its primary endpoint.
Trial details
- Drug
- Divesiran
- Treats
- Polycythemia Vera
- Phase
- Phase 2
- Result
- Met endpointThe 36-week, randomized, double-blind, placebo-controlled portion of the Phase 2 trial evaluating divesiran (6 mg/kg) administered subcutaneously (s.c.) every six weeks (Q6W) or every twelve weeks (Q12W) met its primary endpoint and secondary endpoints.
- Safety
- The primary endpoint was the proportion of patients achieving a response, which was defined as the absence of phlebotomy and maintenance of hematocrit (HCT) below 45% during weeks 18-36. • Importantly, both divesiran dose groups showed substantial primary endpoint efficacy with response rates of…
- Sponsor
- Silence Therapeutics Nasdaq: SLN
- Dates
- Announced Aug 10, 2026, 7:57 AM ET (SEC 8-K filing time)
About this trial
This Phase 2 trial tested Divesiran in Polycythemia Vera. Silence Therapeutics reported that the trial met its primary endpoint.
Sources
- Source: SEC EDGAR 8-K (EX-99.1)
For information only. Not investment or medical advice. Prices are historical, from consolidated market data, and may contain errors. Always check the original source.